Advancing Ovarian Cancer Treatment: The Latest Insights on PARP Inhibitors from ASCO 2023

Abstract

Ovarian cancer (OC) belongs to the most common malignancies in women and remains the leading cause of mortality among gynecological cancers. Poly (ADP-ribose) polymerase (PARP) inhibitors have shown significant promise in the treatment of OC. Drawing on the latest insights from the American Society of Clinical Oncology (ASCO 2023) annual congress, this review summarizes the data of the recent trials evaluating PARP inhibitors, as well as discusses remaining therapeutic challenges such as drug resistance and the quest for novel predictive biomarkers in OC. The ongoing research presented at the 2023 ASCO annual meeting heralds a hopeful future for OC patients, with PARP inhibitors at the forefront of this paradigm shift. PEER REVIEWED ARTICLE Peer reviewers: Dr David König (University Hospital Basel, Basel, Switzerland); Dr Priska Bützberger (Cantonal Hospital Baden, Baden, Switzerland) Submitted: July 20, 2023 CEST; Accepted: November 28, 2023 CEST